Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2022-07-01
|
| シリーズ: | Microbial Cell Factories |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12934-022-01873-7 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|